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Abstract
Background—Drug resistance poses a significant challenge for the successful application of
highly active antiretroviral therapy (HAART) globally. Furthermore, emergence of HIV-1 isolates
that preferentially utilize CXCR4 as a coreceptor for cell entry, either as a consequence of natural
viral evolution or HAART use may compromise the efficacy of CCR5 antagonists as alternative
antiviral therapy.
Methods—We sequenced the pol gene of viruses from 45 individuals failing at least six months
of HAART in Durban, South Africa to determine the prevalence and patterns of drug resistance
mutations. Coreceptor usage profiles of these viruses and those from 45 HAART-naive individuals
were analyzed using phenotypic and genotypic approaches.
Results—Ninety-five percent of HAART-failing patients had at least one drug resistance
mutation. Thymidine analog mutations (TAMs) were present in 55% of patients with 9% of
individuals possessing mutations indicative of the TAM1 pathway, 44% had TAM2 while 7% had
mutations common to both pathways. Sixty percent of HAART-failing subjects had X4/dual//
mixed-tropic viruses compared to 30% of HAART-naïve subjects (p<0.02). Genetic coreceptor
usage prediction algorithms correlated with phenotypic results with 60% of samples from
HAART-failing subjects predicted to possess CXCR4-using (X4/dual/mixed viruses) versus 15%
of HAART-naïve patients.
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Conclusions—The high proportion of TAMs and X4/dual/mixed HIV-1 viruses among patients
failing therapy highlight the need for intensified monitoring of patients taking HAART and the
problem of diminished drug options (including CCR5 antagonists) for patients failing therapy in
resource-poor settings.
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Coreceptor usage; viral tropism; antiretroviral drug resistance; HAART-failing patients; HAART-
naïve patients
Introduction
HIV/AIDS is the leading cause of death in sub-Saharan Africa and South Africa has the
highest number of HIV infections worldwide 1. HIV-1 subtype C (HIV-1C) is responsible
for the majority of infected individuals in South Africa and worldwide 2. Access to HAART
in South Africa has increased dramatically since the launch of the Operational Plan for
Comprehensive HIV and AIDS Care and Treatment in 2003 3. However, antiretroviral drug
coverage in sub-Saharan African remains low and it was estimated that in 2009, only 37% of
patients eligible for treatment according to the World Health Organization guidelines were
receiving it 4.
Despite the suppression of HIV-1 plasma viral load by HAART to undetectable levels, viral
transcription persists 5–6 and this can lead to the emergence and persistence of drug
resistance, which has significant public health implications. Most developing countries rely
on clinical or immunological algorithms to monitor the effectiveness of HAART 7, which
may result in a delay in the switching of failing HAART regimens. The delay in the
switching of failing HAART regimens in the developing world, where WHO guidelines
recommend the use of 2 nucleoside reverse-transcriptase inhibitors (NRTIs) and one non-
nucleoside reverse-transcriptase inhibitor (NNRTI) as first line therapy may in turn result in
the accumulation of thymidine analog mutations (TAMs) which are associated with broad
cross resistance and may therefore limit the options available for alternative regimens.
Recent studies have highlighted this emerging problem 8–11.
In addition to concerns regarding the emergence of TAMs in resource-poor settings, there
are suggestive data that individuals failing HAART may have a higher proportion of
CXCR4-utilizing viruses compared to antiretroviral-naïve patients even after controlling for
the level of immunodeficiency between the groups 12–13. CXCR4 (X4) and dual-tropic
(R5X4/dual) viruses are associated with rapid disease progression and emerge in the late
chronic phase of disease in a significant proportion of patients 14–15. However, the switch to
X4 viruses appears to be significantly less common for HIV-1C, even in late stages of
disease 16–20. The predominant utilization of CCR5 by HIV-1C could be interpreted to
suggest that CCR5 antagonists would be more efficacious for this subtype. Therefore,
characterization of viral tropism in HIV-1C could help inform whether CCR5 antagonists
should be used as salvage therapy in patients failing current widely used regimens or as part
of first-line/early regimens for maximum benefit.
Here we investigated the drug resistance mutational pathways and factors associated with
failure of HAART among HIV-1C infected patients in a setting where monitoring relies
mainly on clinical and immunological algorithms. Furthermore, we determined coreceptor
utilization profiles of HIV-1C viruses from individuals initiating or failing HAART to assess
the usefulness of CCR5 antagonists as first-line or salvage therapy. We also explored the
accuracy of env sequence based genotypic predictive algorithms in assessing the prevalence
of R5 and CXCR4-using viruses in these patients.
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Study participants were recruited from the Sinikithemba outpatient HIV/AIDS clinic at
McCord Hospital in Durban, South Africa. Patients were included in the ARV-naïve cohort
if they were at least 18 years of age, had a known HIV infection and had no prior history of
HAART (the use of single dose nevirapine for the prevention of mother to child HIV
transmission was not an exclusion criteria). Patients who met these criteria, had CD4+ T-cell
counts ≤ 200 cells/µl or displayed AIDS defining clinical features according to WHO
staging irrespective of CD4 counts or viral loads were recruited into this study. Patients were
included in the ARV-failing arm if they were at least 18 years of age, had a known HIV
infection, HIV-1 RNA load of ≥5,000 copies/ml and had at least 6 months of uninterrupted
HAART. HAART-failing patients were also recruited into the study if they were clinically
assessed to be failing therapy irrespective of viral loads or CD4+ T-cell counts. All study
participants gave written informed consent and the study was approved by all participating
institutional review boards.
Sample collection, viral load and CD4 measurement
CD4+ T-cell counts were determined from fresh blood from all participants by standard flow
cytometry on a FACSCalibur (Becton-Dickinson, Franklin Lakes, NJ, USA) according to
the manufacturer’s instructions. Plasma viral loads were measured using the COBAS
AmpliPrep/COBAS Amplicor HIV-1 Monitor Test, version 1.5 (Roche Diagnostics,
Rotkruez, Switzerland).
Genotypic resistance testing
Genotypic resistance testing was done from plasma samples using the Viroseq HIV-1
Genotyping System (Celera Diagnostics, CA, USA) as directed by the manufacturer.
Phenotypic coreceptor analysis
Coreceptor usage of viruses from patient plasma samples was determined using the
enhanced sensitivity Trofile co-receptor tropism assay (Monogram Biosciences Inc., South
San Francisco, California, USA) 21–22. The Trofile® assay is a commercial, standardized
cell-based approach for determination of coreceptor usage by plasma-derived HIV-1
envelope proteins 23–24.
Envelope sequence analysis
cDNA synthesis, envelope amplification and cloning were done as previously described 25.
Full-length env from 20 ARV-failing patients and 20 ARV-naïve patients was cloned into
the pcDNA3.1D/V5-His-TOPO vector (Invitrogen). Sequencing was done using the ABI
PRISM Big Dye Terminator Cycle Sequencing Ready Reaction kit version 3.1 (Applied
Biosystems, CA, USA). Sequences were assembled and edited using Sequencher 4.8 and
aligned with Mega 4. Phylogenetic trees were constructed in Paup 4.0 and visualized using
Treeview 1.6.6. Coreceptor utilization was predicted using various publicly available or
published sequence-based predictive algorithms 26–29.
Statistical analysis
All statistical analysis was done using Graph Pad Prism 5. Factors associated with tropism
were assessed using unpaired t tests, Fisher’s exact tests and logistical regression analysis.
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Nucleotide sequence accession numbers
The sequence data obtained from this study have been submitted to GenBank under
accession numbers GU080160 to GU080199.
Results
Demographic and clinical characteristics
Forty five HAART-naïve and 45 HAART-failing patients were recruited. Patient
demographic and clinical data are summarized in Table 1. At the time of analysis, HAART-
naïve patients had a lower median CD4+ T-cell count (123 cells/mm3) than HAART-failing
(174 cells/mm3) subjects (p=0.036). However, the median CD4+ T-cell count of HAART-
naïve patients was higher than the nadir median CD4+ T-cell count (57 cells/mm3)
(p=0.0004) of HAART-failing patients. HAART-naïve patients had significantly higher
median plasma viral load of 44,042 copies/ml compared to 6,653 copies/ml for HAART-
experienced participants (p=0.001). For patients failing treatment, the median duration on
therapy was 29 months.
Genotypic drug resistance typing
Drug resistance results were obtained for 43 of the 45 HAART-failing patients. Resistance
testing was also performed for ten HAART-naïve patients. The only drug resistance
mutation observed in the HAART-naïve individuals was in one patient with the NNRTI-
associated E138A mutation. Three HAART-naive patients had minor protease inhibitor (PI)
resistance mutations, one patient with mutations L10V and T74S/T, another had mutation
A71T and the third patient had the T74S/T mutation. Of the 45 HAART-failing patients,
51.1% were on South African national treatment guidelines Regimen 1A (d4T, 3TC and
EFV); 4.4% were on Regimen 1B (d4T, 3TC and NVP), 29% were on AZT, 3TC and EFV;
8.9% were on AZT, 3TC and NVP; 2.2% were on AZT, d4T, ddI and NVP and 4.4% were
on AZT, d4T, 3TC and EFV. Twenty seven (60%) of the patients were on previous ARV
therapy as detailed in table 1.
The specific drug resistance mutations detected in HAART-failing patients, and their
frequencies are shown in figure 1. Mutations to all three major classes of drugs were noted.
Forty one of the 43 (95%) ARV-failing patients possessed at least one drug resistance
mutation. Ninety one percent of patients had at least one drug resistance mutation against 2
classes of drugs (NRTI and NNRTI). Nineteen percent had at least one resistance mutation
against all 3 classes of drugs (NRTI, NNRTI and PI). For PI, only one minor mutation
(T74S) was present in 9 (21%) of the HAART-failing patients (data not shown).
M184V/I, present in 87% of HAART-failing patients was the most common NRTI mutation
detected. Thymidine analog resistance mutations (TAMs) were detected in 55% of patients.
The TAM1 pathway NRTI mutations M41L and T215Y, associated with intermediate to
high level resistance to AZT and d4T and low level resistance to ddI, ABC and TDF 30 were
present in approximately 9% of patients. Neither an insertion at codon 69 nor the L210W
mutation which is also indicative of the TAM1 pathway was noted. The TAM2 pathway
mutations present were D67N, K70R, T215F and K219EQR. Forty four percent of patients
had TAM2 pathway mutations. Seven percent of patients possessed both TAM1 and TAM2
mutations and 16% had three or more TAMs.
Approximately 91% of patients had resistance to 3TC and FTC, 19% had high or
intermediate level resistance to AZT as defined by the Stanford database resistance scores
(http://hivdb.stanford.edu/) (see also figure 1 legend). Fourteen percent had high or
intermediate level resistance to d4T while 9% had high or intermediate level resistance to
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ddI. High or intermediate level resistance to ABC was noted in 28% of patients, while only
7% displayed high or intermediate level resistance to TDF (Figure 1A).
NNRTI mutations noted are summarized in Figure 1B. The most common NNRTI resistance
mutation was V106M, found in 49% of HAART-failing participants. The K103N (40%) and
G190A (27%) mutations were also relatively common but no G190S mutations were present
in any of the patients. V106M and K103N both cause high-level resistance to 3 of the 4
NNRTI: nevirapine (NVP), delavirdine (DLV) and efavirenz (EFV) but has no effect on
etravirine (ETR). G190A causes high level resistance to NVP, intermediate resistance to
EFV and low level resistance to ETR. This mutation also increases susceptibility to DLV 31.
Interestingly, the M230L mutation, associated with high level resistance to ETR and
uncommon (<5%) in both subtype B and C NNRTI-failing patients, occurred at an unusually
high frequency of 13.3% in this cohort. Ninety-five percent of patients had mutations
associated with high level resistance to NVP, 93% had high/intermediate level EFV
resistance mutations. Ninety three percent displayed high or intermediate level resistance to
DLV, with 49% displaying high/intermediate level resistance to ETR (Figure 1B).
Recent studies in southern Africa have highlighted the growing problem of thymidine
analog mutations in patients receiving the World Health Organization (WHO) or national
antiretroviral programmes recommended first-line therapy 9–10, 32. We hypothesized that
these mutations may be increasing as antiretroviral roll-out accelerates, accompanied by
mainly clinical and immunological based monitoring of treatment. We therefore compared
the proportion and patterns of TAM mutations observed in our study, in which patients had
been treated for a median of 29 months, with data reported from an earlier study from the
same healthcare facility in patients (median treatment duration of 11 months) also following
the South African national antiretroviral treatment and monitoring guidelines. We found that
55% of individuals failing therapy had TAM mutations compared to 32% reported in the
earlier study 10 and there was there was a non-significant trend in the present study for
association of TAMs with duration of treatment (p=0.08) (data not shown).
Coreceptor utilization
Phenotypic coreceptor analysis—Only 83 of 90 samples were available for
phenotypic coreceptor analysis of which 75 samples (32 from ARV-experienced patients
failing treatment and 43 from ARV-naive patients) yielded reportable data from the Trofile
coreceptor tropism assay. Overall, 31/75 (41%) were dual/mixed viruses, 43/75 (57%) were
CCR5-using, and only 1 (1%) was exclusively CXCR4-utilizing. Of the 43 ARV-naive
patients, 30 (70%) possessed R5 viruses compared to 13 (30%) with dual/mixed viruses. No
ARV-naive patients exhibited exclusive X4 viruses. Among the 32 ARV-experienced
patients failing treatment, 13 (41%) possessed R5 viruses, 18 (56%) had dual/mixed
infections while one patient (3%) had X4-only viruses (Figure 2A). Thus patients failing
treatment had a higher percentage (59%) of X4/dual/mixed viruses compared to ARV-naive
patients with 30%, ARV-naive patients had higher proportion of R5 viruses (70%) compared
to patients failing therapy with 41% (p=0.02).
We then sought to determine if there was a relationship between CD4 counts, viral loads and
viral tropism. Patients with X4/dual/mixed viruses had significantly lower nadir CD4+ T-
cell counts compared to those with R5 viruses in both the ART-naive and ART-failing
groups with significant p-values of 0.014 and 0.002 respectively. In logistic regression
analysis, lower CD4 counts (p=0.0004) but not age of patient (p=0.29) or duration on
HAART (p=0.95) treatment were a significant predictor of X4/dual/mixed infections. We
also investigated whether patients with TAMs were more likely to harbour dual/mixed/X4
viruses. Eleven of 16 (69%) HAART-failing patients with TAMs had X4/dual/mixed viruses
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and 5 (31%) had CCR5-using viruses, compared to the respective proportions of 50% dual/
mixed/X4 versus 50% R5 among patients without TAMs (p=0.47) (Figure 2C).
Genotypic analysis of the env gene—HIV-1 envelope sequence determines
coreceptor utilization 28, 33–36. We therefore next sought to assess the extent to which viral
tropism could be predicted by env sequence characteristics. We randomly selected 20
virologically failing and 20 ARV-naïve patients and analyzed full-length env sequences for
predictive coreceptor utilization profiles.
All 40 full-length env clones analyzed phylogenetically clustered with HIV-1 subtype C
references (Figure 3A left panel). Phylogenetic analysis of the pol region also showed that
all the patients clustered with HIV-1 subtype C with the exception of 704MC012F which is
a recombinant of subtypes A and G; 704MC003F which is a recombinant of subtypes A and
C and 704MC006F which is a recombinant of subtypes C and J as confirmed using Simplot
(Figure 3A right panel). The env V3 loop sequences from HAART-naïve and failing
participants are shown in figure 3B. The overall V3 consensus sequence generated for ARV-
naive patients (right panel) had 2 more amino acids than the consensus sequence generated
for ARV-failing patients (left panel). Thirteen (65%) of failures and seventeen (85%) of
ARV-naive patients had a V3 region consisting of 35 amino acids consistent with the
consensus subtype C sequence. Thirty one of 40 (78%) clones analyzed contained the
consensus subtype C GPGQ crown motif sequence.
We next investigated the reliability of V3 loop sequence based predictive algorithms against
the phenotypic results obtained using the Trofile assay. Coreceptor prediction genotypic
methods evaluated here included the 11/25 rule; the overall net V3 charge; the subtype C-
specific position specific scoring matrix (C-PSSM), a web-based coreceptor prediction tool
(http://indra.mullins.microbiol.washington.edu/pssm/) and another web-based coreceptor
prediction tool, Geno2Pheno (http://coreceptor.bioinf.mpi-inf.mpg.de/) 26–29. We also
investigated whether a combined algorithm (combining 3 of the above 4 methods) would
provide a better correlate of the phenotype data. Overall, the combined algorithm correlated
with the Trofile assay results in 87% of cases, compared to 81% for C-PSSM, 78% for the
11/25 rule and 75% for the V3 net charge method and 84% for Geno2Pheno (Table 2). The
combined algorithm and the 11/25 rule correctly identified 90% of R5 sequences, C-PSSM
correctly predicted 85% and the V3 net charge method predicted 71% of R5 viruses while
Geno2Pheno was accurate for 86% of R5 cases. In contrast, the Geno2Pheno method was
the best in accurately predicting X4/dual/mixed at 82%, V3 overall charge method
accurately predicted 81% X4/dual/mixed, the combined algorithm was at 80%, C-PSSM
72% and the 11/25 rule correctly predicted only 55% of X4/dual/mixed viruses. Sensitivity
of these methods was also determined using the Trofile assay as the gold standard. The
Geno2Pheno and V3 charge prediction methods were 82% sensitive in predicting X4/dual/
mixed virus variants followed by the combined algorithm (80%), C-PSSM (73%) and 11/25
rule (46%).
Discussion
Monitoring the emergence and patterns of antiretroviral drug resistance is crucial for the
success and sustainability of treatment programmes. Moreover, as new drugs become
available, there is a growing need to better characterize viruses from both drug naïve and
virologically failing patients to better understand the suitability of these new drugs either as
additional components of the current regimens or as salvage therapy. In this study we
investigated the prevalence and pattern of drug resistance mutations in a cohort of HIV-1
subtype C-infected individuals failing therapy. In addition, since it has previously been
suggested that suboptimal antiretroviral treatment or certain classes of drugs may select for
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the more virulent X4 virus variants 13, we sought to identify correlates of viral tropism in
HAART-naïve and therapy experienced virologically failing patients.
Our results show that in a South African setting where patients are receiving antiretroviral
therapy according to national and WHO guidelines, 95% of patients failing therapy had at
least one drug resistance mutation. The most common NRTI mutation was M184V/I in 87%
of patients; with V106M/A (51%) and K103N (40%) the commonest NNRTI resistance
mutations. These patterns are consistent with data from previous HIV-1C studies 10, 37–39.
However, we also found a high prevalence (13.3%) of the ETR-resistance associated M230L
mutation, which occurs relatively rarely in NNRTI-failing patients. This finding may require
follow-up studies. Data from this study also revealed that 55% of patients failing therapy
had thymidine analog mutations (TAMs) compared to 32% of patients studied from the
same city in 2005–2006 10. Recent studies from Botswana, Malawi and South Africa have
also reported similar high proportions of TAMs in persons failing therapy under public
sector antiretroviral programmes with an apparent bias towards the TAM2 pathway in these
subtype C studies 32, 40–41. In contrast, a recent subtype B study showed that 65% of
virologically failing subjects harboured TAM1 pathway mutations 8 suggesting that there
may be subtype-specific differences in thymidine analog mutation pathways. Other reasons
for TAM pathway mutation differences may include differences in antiretroviral regimens,
nadir CD4+ T-cell count before HAART commencement, duration of treatment before
failure and duration on a failing regimen. Overall, we found that more than 90% of patients
failing therapy had at least one drug resistance mutation and 55% of patients harbored
TAMs. To minimize the loss of future treatment options, improved adherence support
mechanisms and better monitoring algorithms for patients on HAART in resource-poor
settings will be required.
We also investigated here whether HAART-failing HIV-1C-infected patients had higher
proportion of X4/dual/mixed viruses compared to HAART-naïve patients. Although we
found this to be the case, the patients failing HAART had lower median (nadir) CD4+
counts compared to HAART-naïve patients, and individuals possessing X4/dual/mixed
viruses had significantly lower CD4+ T cell counts compared to those with R5-only viruses,
in both the HAART-naïve and HAART-failing arms of this study. These data therefore
suggest that low CD4+ T-cell counts (and by extension the length of infection), rather than
HAART is the possible main cause of X4/dual/mixed viruses, consistent with data from
HIV-1 subtype B studies 12, 40. However, only a longitudinal study can decisively determine
whether there is higher proportion of emergence of X4/dual/mixed viruses in treated versus
HAART-naïve patients with similar CD4+ T-cell counts. Nevertheless, our study underlines
the importance of introducing CCR5 inhibitors relatively early in the course of HIV-1
subtype C infection for possible maximum benefit and to preserve other drugs for salvage
use. Clinical trials are needed to determine the equivalence or superiority of CCR5 inhibitors
as part of first line or early regimens, rather than as salvage therapy in HIV-1C settings.
Finally, the availability of virus phenotype and genotype data allowed us to assess the utility
of V3 loop sequenced based methods for predicting viral tropism. Envelope sequence-based
genotypic coreceptor prediction algorithms offer a simpler and less expensive means of
analyzing viral tropism in patients and could facilitate easier and less expensive
determination of whether a patient can be treated with CCR5 antagonists or not. Our data
show that while genotypic methods are reliable for a majority of cases, they failed to
correctly predict CXCR4-tropism in a significant minority of cases consistent with previous
studies 42. Although the Geno2Pheno and V3 charge methods achieved more than 80%
sensitivity in predicting CXCR4/dual-tropism for this dataset, there remains an urgent need
to further investigate and develop better predictive algorithms, perhaps taking into account
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sequences outside of the V3 and more detailed analysis of V3 loop sequences using newer
technologies able to better characterize V3 loop quasispecies diversity.
In summary, our observations confirm and extend the body of knowledge in examining
coreceptor tropism directly in patients failing currently recommended regimens, and
comparing this with ARV-naïve patients in a HIV-1 subtype C setting. The presence of high
proportions of patients with TAMs suggests that these mutations may be accumulating over
time in this population as a result of inadequate viral suppression, perhaps as a consequence
of poor immunological and/or clinically driven monitoring in the absence of viral load
testing. These results may suggest that in situations where virologic monitoring is not
possible, measures are needed to improve adherence and to develop better monitoring tools.
Comparison of the prevalence of CXCR4-utilizing viruses between ARV-naive prior to
initiating ART with the prevalence among treated patients revealed that there was a high
prevalence of X4/dual/mixed viruses in patients failing treatment, possibly due to lower
nadir CD4 counts in these patients, underlining the need to investigate the possible earlier
use of CCR5 inhibitors before the development of X4/dual/mixed viruses. Our data also
highlight the usefulness and limitations of genotypic coreceptor prediction methods in
assessing whether HIV-1C infected patients can be put on regimens that include CCR5
inhibitors. Longitudinal studies on viral coreceptor evolution in HIV-1C infections are
warranted.
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Figure 1. Frequency of drug resistance mutations and analog resistance mutations (TAMs)
A) shows the frequency of NRTI resistance mutations, thymidine analog mutation
frequencies and number of patients displaying high and intermediate level resistance to
specific NRTIs and B) shows the frequency of NNRTI resistance mutations and the number
of patients showing resistance to specific NNRTIs. According to the Stanford drug
resistance database algorithms for interpretation of resistance, high-level resistance refers to
a genotypic pattern in which isolates have the maximum level of in vitro drug resistance
and/or patients infected with isolates having similar genotypes display little or no virologic
response to treatment with the drug. In low-level resistance, virus isolates have partial in
vitro drug susceptibility and/or patients with viruses of this genotype may have a suboptimal
virologic response to treatment compared with the treatment of a wildtype virus.
Intermediate resistance suggests a degree of drug resistance greater than low-level resistance
but lower than high-level resistance.
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Figure 2. Relationship of viral tropism of ARV-naive and ARV-failing patients
A) Frequency of X4/dual/mixed- and R5-utilizing viruses in patients failing treatment and
treatment-naive individuals. Bar graph indicating results from the trofile assay comparing
the proportion of patients with R5 viruses to those harbouring X4/dual/mixed viruses in
HAART-naive versus HAART-failing patients (p=0.02, Fisher’s exact test). B) CD4 counts
and coreceptor usage in HAART-naive patients and HAART-failing patients. Dot graph
indicating results from trofile assay. ARV-naive patients with X4/D/M viruses had a lower
CD4 count than ARV-naive patients with R5 viruses (p=0.014, unpaired t test). ARV-failing
patients with X4/D/M viruses had a lower CD4 count than ARV-failing patients with R5
viruses (p=0.02, unpaired t test). For ARV-failing patients nadir CD4 counts are
respresented C) Association of TAMs in X4/D/ M viruses. Bar graph indicates trofile assay
results. D/M indicates dual/mixed viruses.
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Figure 3. Neighbour-Joining phylogenetic trees
A) Left panel - Neighbour-Joining phylogenetic tree constructed from the env gene
sequences. All clones highlighted in red cluster closely with subtype C. Right panel -
Neighbour-Joining phylogenetic tree constructed from the pol gene sequences. All patient
samples highlighted in red cluster together with the subtype C reference with the exception
of 704MC012F which clusters with subtype G. Boostrap values more than 70% are shown.
B) Alignment of V3 sequences of clones of ARV-failing and ARV-naïve patients. The panel
on the left indicates V3 sequences in patients failing treatment and the panel on the right
indicates V3 sequences in ARV-naive patients. The crown motif for each sequence is
highlighted in red. All sequences from viruses determined to be X4/dual/mixed by the
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Trofile assay are highlighted in grey and samples with asterisk next to sample number were
not available for analysis in the Trofile assay or did not yield reportable data.
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Age, median years (Q1–Q3) 36 (24–51) 36 (20–78) 0.65
Gender: Female 28 (65%) 27 (60%)
Black race 45 (100%) 45 (100%)
CD4 cell count, median cells/mm3 (Q1–Q3)
Current 174 (9–718) 123 (8–660) 0.036
Nadir 57 (3–197) 0.0004
Vial load, median copies/ml 6, 653 (225-220,010) 44,042 (1,702–1,167,759) 0.0010
Current treatment regimen: Current treatment regimen:
  Regimen 1A (d4T, 3TC, EFV) 23 (51.1%) Regimen 1A (d4T, 3TC, EFV) 23 (51.1%)
  Regimen 1B (d4T, 3TC, NVP) 2 (4.4%) Regimen 1B (d4T, 3TC, NVP) 2 (4.4%)
ZDV, d4T, ddI, NVP 1 (2.2%) ZDV, d4T, ddI, NVP 1 (2.2%)
ZDV, d4T, 3TC, EFV 2 (4.4%) ZDV, d4T, 3TC, EFV 2 (4.4%)
ZDV, 3TC, EFV 13 (29.0%) ZDV, 3TC, EFV 13 (29.0%)
ZDV, 3TC,NVP 4 (8.9%) ZDV, 3TC,NVP 4 (8.9%)
*
Of these, 11/27 (40.8%) had previous history of Regimen 1A. 2/27 (7.4%) had a previous history of d4T, 3TC, NVP and EFV; 2/27 (7.4%) had a
previous history of d4T and NVP and 1/27 (3.7%) each had previous history of the following: AZT, d4T, 3TC, ddI, EFV; d4T, NVP, EFV; AZT,
3TC, NVP, Lopinivir/Ritonivir; AZT, d4T, EFV; AZT, 3TC, Lopinivir/Ritonivir; AZT, d4T, 3TC, NVP; d4T, 3TC; AZT, d4T, NVP; 3TC, ddI,
EFV; AZT, 3TC, EFV; d4T, 3TC, ddI, EFV; and AZT, 3TC,ddI.
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Table 2
V3 loop-based methods for coreceptor usage prediction
Method % of sequences#
correctly predicted





11/25 78 90 55
Overall net V3 charge 75 71 81
C-PSSM 81 85 72
Geno2Pheno 84 86 82
Combined algorithm* 87 90 80
#
R5 refers to viruses using CCR5 only, X4/D/M refers to CXCR4-using viruses (CXCR4-only, dual tropic and mixed populations).
*
In the combined algorithm, concordant results from at least 3 of 4 methods (i.e. the amino acids at positions 11 and/or 25, the overall net V3
charge, C-PSSM prediction and Geno2Pheno prediction) were used.
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